MyoKardia (MYOK) PT Raised to $84 at Wedbush

Go back to MyoKardia (MYOK) PT Raised to $84 at Wedbush

MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi

January 2, 2019 8:00 AM EST

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on December 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491.

... More